Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: A randomized, double-blind, placebo-controlled study

Osteoarthritis and Cartilage

Volumn 18, Issue SUPPL. 1, 2010, Pages

  Moller I ^a   Perez M ^b   Monfort, J ^c   Benito, P ^c   Cuevas, J ^d   Perna, C ^d   Domenech G ^c   Herrero, M ^e   Montell, E ^e   Verges J ^e  

^a Instituto Poal de Reumatologia   (Spain)

^b Umbert Dermatology Institute   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^e BIOIBERICA SA   (Spain)

Author keywords

Chondroitin sulphate; Knee osteoarthritis; Psoriasis

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; CHONDROITIN SULFATE; CONDROSAN; CS BIO ACTIVE; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KNEE OSTEOARTHRITIS; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA SEVERITY INDEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TREATMENT OUTCOME; VISUAL ANALOG SCALE; AGED; COMPLICATION; EPIDEMIOLOGY; MIDDLE AGED; MULTICENTER STUDY; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PATHOLOGY; PROCEDURES;

AGED; ANTI-INFLAMMATORY AGENTS; CHONDROITIN SULFATES; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77953809438     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.01.018     Document Type: Article

References (51)

1. Felson D.T., Lawrence R.C., Dieppe P.A., Hirsch R., Helmick C.G., Jordan J.M., et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000, 133:635-646.
2. Zhang Y., Jordan J.M. Epidemiology of osteoarthritis. Rheum Dis Clin North Am 2008, 34:515-519.
3. Monfort J., Martel-Pelletier J., Pelletier J.P. Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses. Curr Med Res Opin 2008, 24:1303-1308.
4. Hardingham T. Chondroitin sulfate and joint disease. Osteoarthritis Cartilage 1998, 6(Suppl A):3-5.
5. Uebelhart D., Malaise M., Marcolongo R., DeVathairell F., Piperno M., Mailleux E., et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004, 12:269-276.
6. Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
7. Leeb B.F., Schweitzer H., Montag K., Smolen J.S. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000, 27:205-211.
8. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808.
9. Morreale P., Manopulo R., Galati M., Boccanera L., Saponati G., Bocchi L. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996, 23:1385-1391.
10. Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y., Reginster J.Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003, 163:1514-1522.
11. Sarmiento E., Manapat B.H.D., Salido E.O. The efficacy of chondroitin sulfate in the treatment of knee osteoarthritis: a metaanalysis. Osteoarthritis Cartilage 1999, 7(Suppl A):S35.
12. Uebelhart D., Thonar E.J., Delmas P.D., Chantraine A., Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998, 6(Suppl A):39-46.
13. Verbruggen G., Goemaere S., Veys E.M. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002, 21:231-243.
14. Rovetta G., Monteforte P., Molfetta G., Balestra V. Chondroitin sulfate in erosive osteoarthritis of the hands. Int J Tissue React 2002, 24:29-32.
15. Jomphe C., Gabriac M., Hale T.M., Heroux L., Trudeau L.E., Deblois D., et al. Chondroitin sulfate inhibits the nuclear translocation of Nuclear Factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol 2008, 102:59-65.
16. Iovu M., Dumais G., du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 2008, 16(Suppl 3):S14-S18.
17. Monfort J., Pelletier J.P., Garcia-Giralt N., Martel-Pelletier J. Biochemical basis of the effect of chrondroitin sulfate on osteoarthritis articular disease. Ann Rheum Dis 2008, 67:735-740.
18. Bell S., Degitz K., Quirling M., Jilg N., Page S., Brand K. Involvement of NF-kappaB signalling in skin physiology and disease. Cell Signal 2003, 15:1-7.
19. Vergés J., Montell E., Herrero M., Perna C., Cuevas J., Pérez M., et al. Clinical and histopathological improvement of psoriasis in patients with osteoarthritis treated with chondroitin sulfate: report of 3 cases. Med Clin (Barc) 2004, 123:739-742.
20. Vergés J., Montell E., Herrero M., Perna C., Cuevas J., Dalmau J., et al. Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. Dermatol Online J 2005, 11:31.
21. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000, 43:1905-1915.
22. Huskisson E.C. Measurement of pain. J Rheumatol 1982, 9:768-769.
23. Kellgren J.H., Lawrence J.S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957, 16:494-502.
24. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978, 157:238-244.
25. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
26. Lequesne M.G., Mery C., Samson M., Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests. Scand J Rheumatol Suppl 1987, 65:85-89.
27. Mazières B., Combe B., Phan Van A., Tondut J., Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol 2001, 28:173-181.
28. Bucsi L., Poór G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998, 6(Suppl A):31-36.
29. Bourgeois P., Chales G., Dehais J., Delcambre B., Kuntz J.L., Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200mg/day vs chondroitin sulfate 3×400mg/day vs placebo. Osteoarthritis Cartilage 1998, 6(Suppl A):25-30.
30. Uebelhart D. Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 2008, 16(Suppl 3):S19-S21.
31. Picavet H.S., Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004, 63:723-729.
32. Pettey A.A., Balkrishnan R., Rapp S.R., Fleischer A.B., Feldman S.R. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003, 49:271-275.
33. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol 2008, 75:1567-1579.
34. Abdou A.G., Hanout H.M. Evaluation of survivin and NF-kappaB in psoriasis, an immunohistochemical study. J Cutan Pathol 2008, 35:445-451.
35. Victor F.C., Gottlieb A.B., Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003, 21:392-397.
36. Yano S., Banno T., Walsh R., Blumenberg M. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J Cell Physiol 2008, 214:1-13.
37. Lizzul P.F., Aphale A., Malaviya R., Sun Y., Masud S., Dombrovskiy V., et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005, 124:1275-1283.
38. Amigo M., Paya M., De Rosa S., Terencio M.C. Antipsoriatic effects of avarol-3′-thiosalicylate are mediated by inhibition of TNF-alpha generation and NF-kappaB activation in mouse skin. Br J Pharmacol 2007, 152:353-365.
39. Meili-Butz S., Niermann T., Fasler-Kan E., Barbosa V., Butz N., John D., et al. Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats. Eur J Pharmacol 2008, 586:251-258.
40. Lan C.C., Yu H.S., Wu C.S., Kuo H.Y., Chai C.Y., Chen G.S. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of Nuclear Factor-kappaB. Br J Dermatol 2005, 153:725-732.
41. Bhushan Kumar, Ravi Kumar, Inderjeet Kaur Coal tar therapy in palmoplantar psoriasis: old wine in an old bottle?. Int J Dermatol 1997, 36:309-312.
42. Papp K.A., Miller B., Gordon K.B., Caro I., Kwon P., Compton P.G., et al. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006, 54(4 Suppl 1):S164-S170.
43. Gerdes S., Zahl V.A., Knopf H., Weichenthal M., Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008, 159:1116-1123.
44. Cohen A.D., Bonneh D.Y., Reuveni H., Vardy D.A., Naggan L., Halevy S. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol 2005, 85:299-303.
45. Abel E.A. Diagnosis of drug-induced psoriasis. Semin Dermatol 1992, 11:269-274.
46. Clark D.W., Coulter D.M. Psoriasis associated with rofecoxib. Arch Dermatol 2003, 139:1223.
47. Ben-Chetrit E., Rubinow A. Exacerbation of psoriasis by ibuprofen. Cutis 1986, 38:45.
48. Powles A.V., Griffiths C.E., Seifert M.H., Fry L. Exacerbation of psoriasis by indomethacin. Br J Dermatol 1987, 117:799-800.
49. Katayama H., Kawada A. Exacerbation of psoriasis induced by indomethacin. J Dermatol 1981, 8:323-327.
50. Tsankov N., Angelova I., Kanzandjeva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000, 1:159-165.
51. Reshad H., Hargreaves G.K., Vickers C.F. Generalized pustular psoriasis precipitated by phenylbutazone and oxyphenbutazone. Br J Dermatol 1983, 109. 111-13.